Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 1.000% 9/1
-
Market price (% of par)
-
92.75%
-
Total 13F principal
-
$976,407,604
-
Principal change
-
+$976,407,604
-
Total reported market value
-
$910,151,140
-
Number of holders
-
55
-
Value change
-
+$910,150,772
-
Number of buys
-
55
Institutional Holders of ALNYLAM PHARMACEUTICALS INC - NOTE 1.000% 9/1 as of Q3 2023
As of 30 Sep 2023,
ALNYLAM PHARMACEUTICALS INC - NOTE 1.000% 9/1 was held by
55 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$976,407,604
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, Linden Advisors LP, UBS ASSET MANAGEMENT AMERICAS INC, Calamos Advisors LLC, STEELHEAD PARTNERS LLC, Invesco Ltd., ADVENT CAPITAL MANAGEMENT /DE/, CITADEL ADVISORS LLC, READYSTATE ASSET MANAGEMENT LP, and Polar Asset Management Partners Inc..
This page lists
55
institutional bondholders reporting positions
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.